Under the terms of this new agreement, MediLink will receive an upfront payment of
In
The expansion of the collaboration marks a further consolidation of the strategic partnership between MediLink and BioNTech, laying a new foundation for the mutual R&D collaboration in the ADC field.
About MediLink Therapeutics
MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing conjugated drugs with global competitiveness. MediLink has developed its proprietary ™ALIN ® ADC technology platform, enabling the generation of homogeneous ADC with high drug-antibody ratio and improved therapeutic window for the treatment of solid tumors. MediLink aims to provide improved treatment options for global patients and address unmet medical needs. The company is headquartered in
About ™ALIN ®
The Tumor Microenvironment Activable LINker-payload (™ALIN ®) is an innovative ADC platform technology developed by MediLink Therapeutics with proprietary intellectual property rights. It employs dual cleavage mechanisms, operating both extracellularly in the tumor microenvironment and intracellularly in lysosomes. ™ALIN ® possesses high hydrophilicity, homogenous DAR value, excellent plasma stability, and specific tumor accumulation characteristics. In preclinical efficacy and toxicology studies, ADCs developed based on ™ALIN ® exhibited significant therapeutic window. So far, several ADC products based on ™ALIN ® platform have entered into clinical trial stage.